Antitumor effects of IDN5109 on head and neck squamous cell carcinoma

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 329-334

  Sano, Daisuke ^a   Matsuda, Hideki ^a   Ishiguro, Yukari ^a   Nishimura, Goshi ^a   Kawakami, Mariko ^a   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti angiogenesis; Head and neck squamous cell carcinoma; IDN5109; Oral administration; Taxane

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; ORTATAXEL; PACLITAXEL; TAXOID;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; NEOVASCULARIZATION (PATHOLOGY); SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRIDGED COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; TAXOIDS;

EID: 33744481068     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.2.329     Document Type: Article

References (34)

1. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP: Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55-61, 1993.
2. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
3. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178, 2000. (Pubitemid 30172946)
4. Polizzi D, Pratesi G, Tortoreto M, et al: A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res 59: 1036-1040, 1999. (Pubitemid 29135963)
5. Appendino G, Gariboldi P, Gabetta B, Pace R, Bombardelli E and Veterbo D: 14-β-hydroxy-10-deaceyl-baccatin, a new taxane from Himalayan yew (Taxus wallichiana zucc.). J Chem Soc Perkin Trans 1: 2925-2929, 1992.
6. Polizzi D, Pratesi G, Monestiroli S, et al: Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 6: 2070-2074, 2000. (Pubitemid 30305107)
7. Nicoletti MI, Colombo T, Rossi C, et al: IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 60: 842-846, 2000. (Pubitemid 30129512)
8. Colevas AD, Norris CM, Tishler RB, et al: Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17: 3503-3511, 1999. (Pubitemid 29517921)
9. Schoffski P, Catimel G, Planting AS, et al: Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10: 119-122, 1999. (Pubitemid 29090602)
10. Koukourakis MI, Bizakis JG, Skoulakis CE, et al: Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 19: 2305-2309, 1999. (Pubitemid 29392540)
11. Tsukuda M, Mikami Y, Tanigaki Y, et al: Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 9: 161-166, 2004. (Pubitemid 38899748)
12. Katori H, Tsukuda M, Mochimatu I, et al: Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90: 348-352, 2004. (Pubitemid 38250627)
13. Goldspiel BR: Clinical overview of the taxanes. Pharmacotherapy 17: 110S-125S, 1997.
14. Cassinelli G, Lanzi C, Supino R, et al: Cellular bases of the antitumor activity of the novel taxane IDN5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 8: 2647-2654, 2002. (Pubitemid 34856353)
15. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979. (Pubitemid 9114288)
16. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980. (Pubitemid 10073801)
17. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996. (Pubitemid 26384151)
18. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3372, 2001. (Pubitemid 32695027)
19. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990. (Pubitemid 20239995)
20. Sparreboom A, van Asperen J, Mayer U, et al: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035, 1997. (Pubitemid 27113956)
21. Fujita H, Okamoto M, Takao A, Mase H and Kojima H: Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level. Jpn J Cancer Chemother 21: 653-658, 1994. (Pubitemid 24147379)
22. Alnemri ES, Livingston DJ, Nicholson DW, et al: Human ICE/CED-3 protease nomenclature. Cell 87: 171, 1996.
23. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999. (Pubitemid 32250377)
24. Green DR, Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998. (Pubitemid 28406816)
25. Terasima T and Tolmach LJ: Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 3: 11-33, 1963.
26. Sinclair WK and Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450-474, 1966.
27. Withers HR, Mason K, Reid BO, et al: Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer 34: 39-47, 1974.
28. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
29. Miller KD, Sweeney CJ and Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001. (Pubitemid 32176298)
30. Schirner M: Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 19: 67-73, 2000.
31. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987. (Pubitemid 17009577)
32. Tanigaki Y, Nagashima Y, Kitamura Y, Matsuda H, Mikami Y and Tsukuda M: The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 14: 389-395, 2004.
33. Chen Z, Malhotra PS, Thomas GR, et al: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379, 1999. (Pubitemid 29282941)
34. Lau DH, Xue L, Young LJ, Burke PA and Cheung AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14: 31-36, 1999. (Pubitemid 29157732)